<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399747</url>
  </required_header>
  <id_info>
    <org_study_id>Asan_LMP2017-002</org_study_id>
    <nct_id>NCT03399747</nct_id>
  </id_info>
  <brief_title>Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 Study of Abbreviated 3 Cycles of Rituximab plus CHOP (Cyclophosphamide, Adriamycin,
      Vincristine, and Prednisolone) Immunochemotherapy in Patients with Completely Excised
      Localized Gastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma(SATURDAY STUDY)
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>6 to 8 weeks after completion of the 3rd cycle of treatment(each cycle is 28days)</time_frame>
    <description>CT(Computed tomography) / PET-CT(Positron emission computed tomography)/ Colonoscopy(if necessary) by Lugano stage I or II1, Paris stage T1-2NO-1MO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess response rate</measure>
    <time_frame>after completion of the treatment, up to 2years</time_frame>
    <description>CT/ PET-CT/Colonoscopy(if necessary) by Lugano stage I or II1, Paris stage T1-2NO-1MO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess response rate</measure>
    <time_frame>after completion of the treatment, up to 4years</time_frame>
    <description>CT/ PET-CT/Colonoscopy(if necessary) by Lugano stage I or II1, Paris stage T1-2NO-1MO</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess overall survival</measure>
    <time_frame>after completion of the treatment, up to 5years</time_frame>
    <description>CT/ PET-CT/Colonoscopy(if necessary) by Lugano stage I or II1, Paris stage T1-2NO-1MO</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Abb-R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abb-R-CHOP</intervention_name>
    <description>Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma
3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy</description>
    <arm_group_label>Abb-R-CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completely Excised LocalizedGastrointestinal CD20 (+) DLBCL(Diffuse Large B-cell
             Lymphoma )

          -  CD 20, CD5, CD10, MUM-1, BCL-6, BCL-2, Ki-76, EBV(Epstein-Barr virus )positive

          -  Lugano Criteria: Stage I, II1

          -  Paris Criteria: T1-2NO-1MO

          -  Stage-adjusted International Prognostic Index: 0-1

          -  A patient who has not previously received chemotherapy or radiation treatment for the
             DLBCL

          -  ECOG(Eastern Cooperative Oncology Group ) :0-2

          -  In case of patients who do not have any residual lesion due to complete surgical
             removal of lymphoma I. A patient who has been confirmed to have no residual lesion in
             the CT conducted following surgery or Ii. Preoperative imaging confirmed as the first
             phase of a single lesion and post-operative lesion finding that the patient has been
             confirmed with

          -  In case of a 50 % or higher cardiac output when there is no clinically significant
             abnormality in MUGA(multiple gated acquisition scan) or deep frequency

          -  If appropriate renal function (below serum creatinine 2.0 mg dL or an estimated
             glomerule filtration rate of 40 mL / mill1.73m2 or higher)

          -  If the appropriate liver function is present (serum bilirubin), less than three times
             the normal upper limit of AST(aspartate aminotransferase ) (non-hepatic) unless the
             serubin is caused by Gilbert syndrome or originated from a non-hepatic ;

          -  Proper Bone marrow function (ANC-1500mm 3 or higher, number of platelets &gt; 755mm3, and
             hemoglobin 9.0 g/L or higher) If the screening in the CS(cerebrospinal fluid)F is not
             acceptable, the dose is given in - 7

          -  For males, blocking contraceptive methods such as condoms are required at least 6
             months from the date of the last administration of the cancer and such measures are
             agreed

          -  For fertile women, it must be agreed to apply contraceptive measures (oral
             contraceptive pills, in the womb, blocking contraceptive methods, etc.) for at least 6
             months from the date of administration of the last cancer.

          -  decided to participate in this study voluntarily and agree in writing

        Exclusion Criteria:

          -  HIV or HCV(hepatitis C virus) positive patient. However, HBVhepatitis B virus)
             positive patients using anti-viral therapy are allowed

          -  Patient with current history of other cancers (e.g. cervical carcinoma in situ,
             treated basal cell carcinoma, early cancer, excluded from the present condition of
             cancer.

          -  pregnant or nursing woman, male or female who do not agree with appropriate
             contraception.

          -  Systemic disease that is inappropriate for administration of anticancer drugs I. A
             patient who within the past 6 months had a clinically significant heart attack
             (non-medical congestive heart failure, symptomatic coronary artery disease, severe
             myocardial infarction) or Ii. Serious neurology and psychiatric disease Iii. Serious
             activity infection Iv. Other medical conditions that are difficult to perform in
             clinical trials

          -  If you are allergic to chemicals used in this study

          -  Patients who receive another test medication during a clinical trial or who is
             administered both chemotherapy, hormone therapy and immunization

          -  Patient with Bulky disease (length of diaphragm 10 cm)

          -  Patient who is unsuitable for participation in a clinical examination according to the
             judgment of a researcher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Cheolwon Suh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

